阿尼芬净和米卡芬净的 MIC 折点优于卡泊芬净，可用于鉴定 FKS 突变的光滑念珠菌菌株和棘白菌素耐药性。
Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2013 Dec;57(12):6361-5. doi: 10.1128/AAC.01451-13. Epub 2013 Sep 23.
Abstract
By CLSI interpretive criteria, anidulafungin and micafungin MICs determined by various methods were sensitive (60 to 70%) and highly specific (94 to 100%) for identifying FKS mutations among 120 Candida glabrata isolates. Anidulafungin and micafungin breakpoints were more specific than CLSI's caspofungin breakpoint in identifying FKS mutant strains and patients with invasive candidiasis who were likely to fail echinocandin treatment (P ≤ 0.0001 for both). Echinocandin MICs were most useful clinically when interpreted in the context of prior echinocandin exposure.
摘要
根据 CLSI 解释标准，通过各种方法确定的安尼拉fungin 和米卡fungin MIC 对鉴定 120 株光滑念珠菌分离株中的 FKS 突变具有高敏感性（60-70%）和高特异性（94-100%）。安尼拉fungin 和米卡fungin 折点比 CLSI 的卡泊芬净折点更能准确识别 FKS 突变株和侵袭性念珠菌病患者，这些患者可能对棘白菌素治疗无效（两者均 P≤0.0001）。当棘白菌素 MIC 与既往棘白菌素暴露情况结合进行解释时，在临床上最具参考价值。
相似文献
1
Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.阿尼芬净和米卡芬净的 MIC 折点优于卡泊芬净，可用于鉴定 FKS 突变的光滑念珠菌菌株和棘白菌素耐药性。
Antimicrob Agents Chemother. 2013 Dec;57(12):6361-5. doi: 10.1128/AAC.01451-13. Epub 2013 Sep 23.
2
Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.通过体内药效学评估优化棘白菌素类药物剂量和敏感性折点判断方法，用于治疗有或无 fks 突变的光滑念珠菌感染。
Antimicrob Agents Chemother. 2012 Nov;56(11):5875-82. doi: 10.1128/AAC.01102-12. Epub 2012 Sep 4.
3
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.棘白菌素类药物（阿尼芬净、卡泊芬净和米卡芬净）对有和无 FKS 耐药突变的光滑念珠菌分离株的体内活性差异。
Antimicrob Agents Chemother. 2012 May;56(5):2435-42. doi: 10.1128/AAC.06369-11. Epub 2012 Feb 21.
4
Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.比较米卡芬净、卡泊芬净和阿尼芬净对一种难以治疗的真菌性机会致病菌光滑念珠菌的疗效。
Antimicrob Agents Chemother. 2012 Mar;56(3):1215-22. doi: 10.1128/AAC.05872-11. Epub 2011 Dec 27.
5
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .棘白菌素类药物对. 的自发突变频率和突变率各不相同。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
6
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.10 年间血流感染分离株全球采集的光滑念珠菌分离株中 fks 突变的频率。
Antimicrob Agents Chemother. 2014;58(1):577-80. doi: 10.1128/AAC.01674-13. Epub 2013 Oct 14.
7
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.棘白菌素类耐药性在光滑念珠菌中的增加：临床失败与 FKS 突变和最低抑菌浓度升高相关。
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
8
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.棘白菌素 MIC 与既往棘白菌素暴露的光滑念珠菌侵袭性念珠菌病患者的治疗结局相关。
Antimicrob Agents Chemother. 2013 Aug;57(8):3528-35. doi: 10.1128/AAC.00136-13. Epub 2013 May 13.
9
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.重新审视棘白菌素类药物和念珠菌的临床折点：整合分子、临床和微生物学数据，以制定出基于物种的解释标准。
Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.
10
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.针对念珠菌属对卡泊芬净、阿尼芬净和米卡芬净的药敏试验，其最低抑菌浓度（MIC）与结果的相关性：分析及MIC解释性折点建议
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
引用本文的文献
1
Inter-laboratory variability of caspofungin MICs for isolates - an Irish tertiary hospital experience.卡泊芬净对分离株的最低抑菌浓度（MIC）的实验室间变异性——一家爱尔兰三级医院的经验
Access Microbiol. 2023 Oct 9;5(10). doi: 10.1099/acmi.0.000617.v4. eCollection 2023.
2
Clinical utility of antifungal susceptibility testing.抗真菌药敏试验的临床应用
JAC Antimicrob Resist. 2022 Jun 28;4(3):dlac067. doi: 10.1093/jacamr/dlac067. eCollection 2022 Jun.
3
Comparison of Six Antifungal Susceptibilities of 11 Species Using the VITEK2 AST-YS08 Card and Broth Microdilution Method.采用 VITEK2 AST-YS08 卡和肉汤微量稀释法比较 11 种真菌的六种抗真菌药敏性。
Microbiol Spectr. 2022 Apr 27;10(2):e0125321. doi: 10.1128/spectrum.01253-21. Epub 2022 Apr 6.
4
Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance.酵母抗真菌药敏试验的商业方法：作为耐药性预测指标的优势与局限性
J Fungi (Basel). 2022 Mar 17;8(3):309. doi: 10.3390/jof8030309.
5
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.瑞士念珠菌血症的流行病学趋势：一项为期15年的FUNGINOS调查。
Open Forum Infect Dis. 2021 Sep 17;8(10):ofab471. doi: 10.1093/ofid/ofab471. eCollection 2021 Oct.
6
Can We Improve Antifungal Susceptibility Testing?能否改进抗真菌药物敏感性检测？
Front Cell Infect Microbiol. 2021 Sep 10;11:720609. doi: 10.3389/fcimb.2021.720609. eCollection 2021.
7
Genotyping, antifungal susceptibility, enzymatic activity, and phenotypic variation in Candida albicans from esophageal candidiasis.食管念珠菌病中白色念珠菌的基因分型、抗真菌药敏性、酶活性和表型变异。
J Clin Lab Anal. 2021 Jul;35(7):e23826. doi: 10.1002/jcla.23826. Epub 2021 May 14.
8
Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.抗真菌药敏试验在侵袭性真菌感染管理中的作用及解读
J Fungi (Basel). 2020 Dec 30;7(1):17. doi: 10.3390/jof7010017.
9
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.瑞士出现耐棘白菌素的白念珠菌和光滑念珠菌。
Infection. 2020 Oct;48(5):761-766. doi: 10.1007/s15010-020-01475-8. Epub 2020 Jul 13.
10
Clinical and Laboratory Development of Echinocandin Resistance in : Molecular Characterization.棘白菌素耐药性的临床与实验室研究进展：分子特征分析
Front Microbiol. 2019 Jul 11;10:1585. doi: 10.3389/fmicb.2019.01585. eCollection 2019.
本文引用的文献
1
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?使用CLSI和EUCAST方法检测念珠菌属对卡泊芬净的最低抑菌浓度（MIC）的实验室间变异性：临床实验室是否应该检测这种药物？
Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42. doi: 10.1128/AAC.01519-13. Epub 2013 Sep 9.
2
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.棘白菌素 MIC 与既往棘白菌素暴露的光滑念珠菌侵袭性念珠菌病患者的治疗结局相关。
Antimicrob Agents Chemother. 2013 Aug;57(8):3528-35. doi: 10.1128/AAC.00136-13. Epub 2013 May 13.
3
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.棘白菌素类耐药性在光滑念珠菌中的增加：临床失败与 FKS 突变和最低抑菌浓度升高相关。
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
4
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.棘白菌素治疗失败的独立危险因素是侵袭性念珠菌病（由光滑念珠菌引起）患者存在 FKS 突变而不是 MIC。
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
5
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.比较 Sensititre YeastOne 比色法抗真菌药敏检测板与 CLSI 微量稀释法对抗真菌药物对念珠菌属的药敏试验，采用新的临床折点和流行病学切点值。
Diagn Microbiol Infect Dis. 2012 Aug;73(4):365-8. doi: 10.1016/j.diagmicrobio.2012.05.008. Epub 2012 Jun 20.
6
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.比较二甲基亚砜和水作为 EUCAST 方法进行棘白菌素药敏试验的溶剂。
J Clin Microbiol. 2012 Jul;50(7):2509-12. doi: 10.1128/JCM.00791-12. Epub 2012 Apr 25.
7
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.治疗策略对念珠菌血症和其他形式侵袭性念珠菌病患者结局的影响：随机试验的患者水平定量评价。
Clin Infect Dis. 2012 Apr;54(8):1110-22. doi: 10.1093/cid/cis021. Epub 2012 Mar 12.
8
EUCAST technical note on anidulafungin.EUCAST 关于安尼鲁单抗的技术说明。
Clin Microbiol Infect. 2011 Nov;17(11):E18-20. doi: 10.1111/j.1469-0691.2011.03647.x. Epub 2011 Sep 16.
9
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.重新审视棘白菌素类药物和念珠菌的临床折点：整合分子、临床和微生物学数据，以制定出基于物种的解释标准。
Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.
10
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.比较欧洲抗菌药物敏感性试验委员会 (EUCAST) 和 Etest 方法与 CLSI 肉汤微量稀释法检测念珠菌属对棘白菌素类药物敏感性。
J Clin Microbiol. 2010 May;48(5):1592-9. doi: 10.1128/JCM.02445-09. Epub 2010 Mar 24.
Zotero 插件